Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G M Milano

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 2, 2010
Retrospective survey on the off-label use of posaconazole in pediatric hematology patientsS Cesaro, G M Milano, F Aversa
Attualita Dentale|September 18, 1988
[Malocclusion involving the joint]V Manetti, A Manetti, G M Milano
Pediatric Blood & Cancer|March 25, 2009
Congenital glioblastomaG M Milano, C Cerri, V Ferruzzi, et al.
Pediatric Blood & Cancer|July 28, 2005
Temozolomide in resistant or relapsed pediatric solid tumorsL De Sio, G M Milano, A Castellano, et al.
BJU International|July 31, 2003
Neurovesical dysfunction in children after treating pelvic neoplasmsG Mosiello, C Gatti, M De Gennaro, et al.
Bone Marrow Transplantation|January 26, 2010
Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's HospitalI Ilari, M A De Ioris, G M Milano, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|June 5, 2004
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of ageA Donfrancesco, A Jenkner, A Castellano, et al.
ESMO Open|February 5, 2025
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcomaM Casanova, C M Albert, F Bautista, et al.
ESMO Open|February 6, 2026
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group networkG G Baldi, A M Frezza, C Biagioni, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|December 2, 2010
Retrospective survey on the off-label use of posaconazole in pediatric hematology patientsS Cesaro, G M Milano, F Aversa
Attualita Dentale|September 18, 1988
[Malocclusion involving the joint]V Manetti, A Manetti, G M Milano
Pediatric Blood & Cancer|March 25, 2009
Congenital glioblastomaG M Milano, C Cerri, V Ferruzzi, et al.
Pediatric Blood & Cancer|July 28, 2005
Temozolomide in resistant or relapsed pediatric solid tumorsL De Sio, G M Milano, A Castellano, et al.
BJU International|July 31, 2003
Neurovesical dysfunction in children after treating pelvic neoplasmsG Mosiello, C Gatti, M De Gennaro, et al.
Bone Marrow Transplantation|January 26, 2010
Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's HospitalI Ilari, M A De Ioris, G M Milano, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|June 5, 2004
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of ageA Donfrancesco, A Jenkner, A Castellano, et al.
ESMO Open|February 5, 2025
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcomaM Casanova, C M Albert, F Bautista, et al.
ESMO Open|February 6, 2026
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group networkG G Baldi, A M Frezza, C Biagioni, et al.
Pageof 1